Early screening marker for biliary atresia based on neonatal blood spot metabolite and application of early screening marker

Abstract

The invention provides application of a biomarker. The biomarker is characterized in that the biomarker is selected from one or more of the following specific biomarkers: A. Glutamic acid; B, indoleacetic acid (Indoleaceticacid); C, [alpha]-ketoisovalerate (alpha-ketoisovalerate), and C, [alpha]-ketoisovalerate ([alpha]-ketoisovalerate); D, ketoleucine (Ketoleucine) is used as a raw material; E. 2-hydroxyglutaric acid (2-hydroxyglutaric acid), and E. 2-hydroxyglutaric acid (2-hydroxyglutaric acid); F, taurohyocholic acid (THCA); G, taurocholic acid (TCA); and H, glycocholic acid (GCA). The application is used for preparing a screening kit for detecting early risk of neonatal biliary atresia.

Description

technical field [0001] The present invention relates to the medical field, in particular to an early screening marker for biliary atresia based on neonatal blood spot metabolites, its application and its screening method. Background technique [0002] Biliary atresia (BA) is a cholestatic disease in infancy, characterized by progressive inflammation, obstruction, and rapid liver fibrosis of extrahepatic and extrahepatic bile ducts, and has become the most common cause of pediatric liver transplantation [Hartley JL et al., Biliary atresia. The Lancet, 2009, 374(9702):1704-1713]. The incidence rate of biliary atresia is 1:8000-1:18000 surviving births, with most cases reported in Asia, and the incidence rate of biliary atresia in my country is about 4-5 times that of western countries [SokolRJ et al. Science, 2003, 37(1):4-21; Sanchez-Valle et al. Biliary atresia: epidemiology, genetics, clinical advances, and public health. Frontiers in Pediatrics, 2017, 64(1):285-305]. H...

AI Technical Summary

Problems solved by technology

[0005] For example: in the prior art, the differences in serum microRNA expression profiles of children with biliary atresia and cholestatic infantile hepatitis syndrome were compared for the diagnosis of biliary atresia, but microRNA is unstable and easy to degrade

[0006] Another example: the prior art discloses sulfonated bile acid enzyme fluorescence capillary analysis method and enzyme fluorescence quantitative kit, which are suitable for early detection of neonatal jaundice, but it is difficult to distinguish the subtypes of infant jaundice disease

[0007] Another example: the prior art discloses the ratio of taurochenodeoxycholic acid to chenodeoxycholic acid in serum as a diagnostic marker for biliary atresia in newborns, but the specificity for distinguishing biliary atresia from other infantile cholestatic diseases is not high

[0008] In addition, existing potential diagnostic markers for biliary atresia all rely on large amounts of serum

Blood drawing of asymptomatic newborns or infants is poorly feasible and risky

The blood test of children with obvious symptoms often misses the optimal treatment window period, and early screening of newborn babies cannot be carried out

Images